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Outcomes assessed in the review
The primary outcome was the reduction of the left ventricular mass or the left ventricular mass index, given as the percentage change from baseline value. Other outcomes included the reduction of posterior wall and septal thickness, as percentage change from the baseline value.
How were decisions on the relevance of primary studies made? Two investigators independently examined the identified studies, and evaluated each study for the fulfilment of all predetermined inclusion criteria using a checklist. On the basis of criticisms of the first meta-analysis, two previously accepted studies were excluded. These comments were made by Fagard (see Other Publications of Related Interest), who considered one study to have an inappropriate design and the other to have the treatment effect confounded by exercise training.
Assessment of study quality
The authors did not state that they assessed validity.
Data extraction
The data were extracted according to the prefixed scheme performed in the previous review, in which the following data were extracted: the number of patients (men or women); race; age; previously untreated or therapy discontinued before inclusion in the study; antihypertensive drug class; the dosage of each drug used; the duration of treatment; the number of patients evaluated; the duration of therapy (longest follow-up); pre-treatment systolic and diastolic BP; pretreatment left ventricular mass or left ventricular mass index; pretreatment posterior wall and septal wall thickness; changes in systolic and diastolic blood pressures in absolute and/or relative percentage terms; change in left ventricular mass index in absolute and/or relative terms; and changes in posterior wall and septal wall thickness in absolute and/or relative terms. Each treatment arm was taken as a separate observation.
Methods of synthesis
How were the studies combined? Statistical methods and procedures were performed as in the first meta-analysis, in which all treatment arms of the same drug class were combined and weighted according to the number in each individual study.
How were differences between studies investigated?
The authors did not state how differences between the studies were investigated.
Results of the review
Fifty RCTs (N=1,715) with 102 study arms were used to evaluate the outcomes: 165 patients in 13 placebo arms and 1,550 patients in 89 active treatment arms.
The number of treatment arms for each drug class were: for diuretics, 15 (N=304); for blockers, 23 (N=367); for calcium-channel blockers, 26 (N=441); and for ACE-inhibitors, 25 (N=438).
A direct comparison between two hypertensive drugs was not possible due to the small numbers of studies comparing similar drugs.
The absolute decreases in the outcome parameters were as follows.
Systolic BP: placebo, 2.9 (SD=2.8) mmHg; active 11.9 (SD=4.3) mmHg; P<0.001.
Diastolic BP: placebo, 2.6 (SD=2.7) mmHg; active, 13.6 (SD=3.8) mmHg; P<0.001. Posterior wall thickness: placebo, 0.8 (SD=4.2) mm; active, 6.4 (SD=6.0) mm; P<0.01.
Septal wall thickness: placebo, 0.3 (SD=1.0) mm; active, 7.1 (SD=6.4) mm; P<0.01. Left ventricular mass: placebo, 5.2 (SD=5.9) g/m2; active, 9.2 (SD=7.9) g/m2; P<0.001.
Differences held true after taking account of therapy, age, pre-treatment BP and decrease in BP during treatment.
The overall decrease of left ventricular mass after 26 weeks of treatment was 9.2% (95% confidence interval, CI: 7.6, 10.8) from an average pre-treatment value of 136 g/m2. The decrease of left ventricular mass was more marked, the greater the pre-treatment value of left ventricular mass (correlation, r=0.53, P<0.001).
Similar relationships were found for changes in posterior and septal wall thickness (r=0.27, P<0.05 and r=0.24, P<0.06, respectively). The decrease in left ventricular mass index was greater with a greater reduction in systolic BP (partial r=0.26, P<0.05) adjusted for pre-treatment values, and with a greater reduction in diastolic BP (r=0.36, P<0.001). Left ventricular mass also decreased more with a greater fall in diastolic BP (partial r=0.28, P<0.05) adjusted for pretreatment values. The determinants of reduction in left ventricular hypertrophy were the pre-treatment left ventricular mass index, the decrease in BP and the duration of treatment.
A significant difference was detected in the change in left ventricular mass index among the four antihypertensive drug classes (P<0.01) after accounting for systolic BP and age. After weighting for the number of patients, the decreases in left ventricular mass index were as follows: ACE-inhibitors, 11.8% (95% CI: 9.0, 14.5); calcium-channel blockers, 11.1% (95% CI: 7.8, 13.7); blockers, 4.5% (95% CI: 1.2, 7.3); diuretics, 8.6% (95% CI: 3.9, 11.1). ACE inhibitors and calcium-channel blockers led to a greater decrease in both left ventricular mass index (P<0.01 and P<0.05, respectively, after Bonferroni correction) and posterior wall thickness (P<0.05) than blockers. No difference was noted for changes in septal wall thickness.
Authors' conclusions
The reduction of left ventricular hypertrophy was determined by the decrease in systolic BP, duration of antihypertensive therapy and antihypertensive drug class.ACE inhibitors and calcium-channel blockers were more potent in reducing left ventricular mass than blockers, with diuretics in the intermediate range.
CRD commentary
This clearly written and presented review included a comprehensive literature search, selection of studies by two investigators according to a predefined checklist of inclusion criteria, and an analysis that accounted for pre-treatment values.
The validity of included studies was not assessed, results from individual studies were not mentioned, and statistical heterogeneity among studies was not assessed. It was unclear if the analysis was performed on an intention to treat basis. The review did not include an evaluation of withdrawals, side-effects or comparative treatment costs of the therapies evaluated.
The use of each treatment arm as a separate observation in the original review was criticised by Fagard (see Other Publications of Related Interest) on the grounds that by so doing, the authors 'gave up the major advantage of the original study design'. Schmeider countered this comment by asserting that in breaking the matching of study arms with different treatments, the resulting meta-analysis was more likely to overlook moderate effects than to overestimate them. The option preferred by the authors would have been to present the results from a paired analysis by pooling the within-study differences for those trials comparing the same two drug classes. This was not possible due to the limited number of studies directly comparing drug classes within a study.
